Follicular thyroid carcinoma (FTC) is the second most common thyroid cancer, accounting for 10-15% of all thyroid malignancies. It originates from follicular cells and shows the same morphological patterns as follicular adenoma histologically — distinction can only be made histopathologically by demonstrating capsular and/or vascular invasion. Preoperative diagnosis cannot be made by fine-needle aspiration biopsy (FNAB) (Bethesda IV: follicular neoplasm). Unlike papillary carcinoma, hematogenous metastasis is the dominant spread route (lung and bone are the most common metastatic sites); lymphatic metastasis is rare (5-10%). Usually occurs between ages 40-60 and in women (F:M = 3:1). Incidence is higher in iodine-deficient regions. Prognosis is slightly worse than papillary carcinoma but still considered good (10-year survival 85-95%).
Age Range
30-60
Peak Age
50
Gender
Female predominant
Prevalence
Uncommon
FTC develops from malignant transformation of thyroid follicular epithelium and is genetically characterized by RAS mutations (N-RAS, H-RAS, K-RAS — in 40-50% of cases) and PAX8-PPARγ gene rearrangements (in 25-60% of cases) — the same mutations are found in follicular adenoma, but additional genetic events accumulate in malignant transformation (TERT promoter mutation, TP53, PIK3CA). BRAF V600E mutation is absent in FTC (unlike papillary carcinoma). Capsular invasion is the penetration of the fibrous capsule by tumor cells — in minimally invasive type only capsular invasion is present, while in widely invasive type there is extensive vascular invasion and extension beyond the capsule. Hematogenous spread occurs as tumor cells invade capsular and parenchymal vessels to reach venous circulation — therefore bone (especially vertebra, pelvis, sternum) and lung are the most common distant metastatic sites. Since FTC preserves follicular differentiation, NIS expression is generally present and it responds to I-131 therapy — however, NIS loss may occur in poorly differentiated or widely invasive variants.
The diagnostic criterion for FTC is histopathology, not imaging — diagnosis is made by demonstrating capsular and/or vascular invasion. The closest clue on imaging is focal loss or irregularity of the hypointense capsular rim on MRI T2. However, this finding has low sensitivity. In clinical practice, the flow of FNAB Bethesda IV → surgery (lobectomy) → histopathological capsule/vascular invasion assessment → definitive diagnosis is followed.
FTC appears on ultrasonography as a solid, hypoechoic, well-defined, and encapsulated nodule — indistinguishable from follicular adenoma on imaging. Halo (pericapsular rim) is usually present but an incomplete or irregular halo may be a clue for capsular invasion. Microcalcifications are typically ABSENT (unlike papillary carcinoma). The nodule is generally wider-than-tall shaped (in minimally invasive type). Heterogeneity, cystic degeneration, and coarse calcifications may be seen in large tumors (>4cm). Irregular margins, capsule disruption, and extrathyroidal extension may be seen in widely invasive type.
Report Sentence
A solid, hypoechoic, encapsulated nodule measuring …x…x… mm is identified in the right/left thyroid lobe; follicular neoplasm should be considered, and adenoma/carcinoma distinction will be made histopathologically.
Doppler vascularity pattern in FTC is variable: perinodular (basket pattern) + varying degrees of intranodular vascularity. In minimally invasive type, dominant perinodular pattern similar to follicular adenoma is seen, while markedly increased intranodular chaotic vascularity may be observed in widely invasive type. FTC's potential for vascular invasion may be reflected by tumor vessels reaching and crossing capsular vessels on Doppler — however, this finding is not specific.
Report Sentence
Color Doppler examination demonstrates mixed perinodular and intranodular vascularity in the nodule, consistent with follicular neoplasm.
On contrast-enhanced CT, FTC appears as a homogeneously to heterogeneously enhancing, encapsulated solid nodule. In minimally invasive type the capsule appears intact, while in widely invasive type capsule irregularity, extracapsular extension, and invasion of surrounding structures may be detected. On non-contrast studies, isodense or slightly hypodense relative to normal thyroid parenchyma. Coarse calcifications may be present (microcalcifications typically absent). CT's most important role is assessment of extrathyroidal extension, tracheal invasion, and mediastinal/vascular relationships in widely invasive FTC. CT is also important for bone and lung metastasis screening.
Report Sentence
On contrast-enhanced CT, an encapsulated, homogeneously/heterogeneously enhancing solid nodule measuring …x…x… mm is identified in the right/left thyroid lobe, consistent with follicular neoplasm; careful evaluation for capsule irregularity and extrathyroidal extension is recommended.
On MRI, FTC shows iso- to hyperintense signal on T2-weighted images. The fibrous capsule appears as a thin hypointense rim on T2 — capsule integrity is better assessed on MRI than CT (superior soft tissue contrast). At the capsular invasion focus, the hypointense rim focally disappears or becomes irregular. On T1, iso- to hypointense relative to parenchyma. Enhancement pattern is variable on contrast-enhanced MRI. On DWI, marked diffusion restriction may be seen in widely invasive type (in regions of high cellular density). MRI is particularly complementary to CT for capsule assessment and extrathyroidal extension detection.
Report Sentence
On MRI, the encapsulated solid nodule in the right/left thyroid lobe demonstrates iso- to hyperintense signal on T2 with focal irregularity/loss of the capsular rim; surgical excision is recommended due to suspicion of capsular invasion.
On preoperative scintigraphy, FTC almost always appears as a cold nodule. On post-thyroidectomy I-131 whole body scintigraphy, FTC generally maintains sufficient NIS expression to show RAI uptake — used for both diagnostic and therapeutic purposes. Bone metastases may appear as focal areas of increased uptake on I-131 scintigraphy. Pulmonary micronodular metastases may appear as diffuse increased uptake. NIS loss may occur in poorly differentiated or widely invasive variants → RAI-resistant disease → assessment with FDG PET-CT may be needed ('flip-flop' phenomenon: as RAI uptake decreases, FDG uptake increases).
Report Sentence
On I-131 whole body scintigraphy, focal radiopharmaceutical uptake is noted in the bone/lung region, consistent with RAI-avid metastatic follicular thyroid carcinoma.
Criteria
Only capsular invasion (no vascular invasion or <4 foci). Capsule mostly appears intact. Prognosis is excellent (95%+ survival).
Distinct Features
Cannot be distinguished from follicular adenoma on imaging. Lobectomy may be curative. Distant metastasis very rare.
Criteria
Widespread vascular invasion (≥4 foci) and/or extracapsular extension. Extrathyroidal spread common. High risk of hematogenous metastasis.
Distinct Features
Large mass with irregular margins extending beyond capsule on imaging. Bone and lung metastases common. Total thyroidectomy + RAI + TSH suppression therapy.
Criteria
Capsule intact but capsular vessel invasion present. Prognosis between minimally invasive and widely invasive.
Distinct Features
Number of vascular invasion foci determines prognosis (<4 foci = good, ≥4 = poor). Imaging appearance similar to adenoma with intact capsule.
Distinguishing Feature
Cannot be distinguished by imaging or cytology — differentiation is made ONLY by demonstrating capsular and/or vascular invasion on histopathology. Both lesions show solid, hypoechoic, encapsulated appearance and FNAB result of Bethesda IV (follicular neoplasm).
Distinguishing Feature
Papillary carcinoma shows microcalcifications (psammoma bodies), taller-than-wide shape, irregular margins, and lymphatic metastasis. FTC lacks microcalcifications, is wider-than-tall, and hematogenous metastasis (bone/lung) is dominant. Cervical LAP → PTC, bone metastasis → FTC is suggested.
Distinguishing Feature
Hurthle cell tumors are markedly hypoechoic, show increased intranodular vascularity, and are always cold on scintigraphy. FTC is generally less hypoechoic with variable scintigraphy findings. Histopathological distinction: Hurthle cell carcinoma consists of oncocytic cells + capsular/vascular invasion.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralWhen FNAB yields Bethesda IV (follicular neoplasm), diagnostic lobectomy is recommended. If capsular and/or vascular invasion is identified on histopathology, FTC is diagnosed and treatment is planned based on risk stratification: in minimally invasive FTC, lobectomy may be sufficient; in widely invasive FTC, completion thyroidectomy + RAI (I-131) therapy + TSH suppression therapy is administered. Follow-up: serum thyroglobulin (as tumor marker) + neck US + I-131 whole body scintigraphy as needed. CT and/or bone scintigraphy for bone and lung metastasis screening. In RAI-resistant disease, FDG PET-CT and tyrosine kinase inhibitors (lenvatinib, sorafenib) are considered. Prognosis is excellent in minimally invasive type (95%+ 10-year survival); worse in widely invasive type (50-70% 10-year survival).
Follicular thyroid carcinoma shows hematogenous spread and can metastasize to bone/lung. Treatment is total thyroidectomy + radioactive iodine ablation. Prognosis is worse than papillary carcinoma but still has good survival rates. FNA yields follicular neoplasm diagnosis requiring surgery.